We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+28.17%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.72B
AUM Growth
+$1.22B
Cap. Flow
+$567M
Cap. Flow %
9.91%
Top 10 Hldgs %
84.78%
Holding
119
New
24
Increased
23
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.2M
2
MDCO
Medicines Co
MDCO
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.9M
4
INCY icon
Incyte
INCY
+$9.54M
5
NKTR icon
Nektar Therapeutics
NKTR
+$7.71M

Top Sells

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$27M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M
4
ZTO icon
ZTO Express
ZTO
+$6.21M
5
SAGE
Sage Therapeutics
SAGE
+$6.14M

Sector Composition

Rank Sector Weight
1 Consumer Staples 34.97%
2 Healthcare 25.04%
3 Consumer Discretionary 17.19%
4 Financials 0.66%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
CALL
Nektar Therapeutics
NKTR
$2.43B
$19.6M 0.34%
66,667
+33,334
+100% +$9.63M
ONC
27
BeOne Medicines Ltd
ONC
$34.1B
$18M 0.31%
400,000
+36,714
+10% +$1.45M
TER icon
28
CALL
Teradyne
TER
$53.3B
$15M 0.26%
+500,000
New +$16.8M
FOLD
29
DELISTED
Amicus Therapeutics
FOLD
$14.1M 0.25%
1,400,000
-500,000
-26% -$4.02M
BMRN icon
30
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$13.6M 0.24%
150,000
+100,000
+200% +$9.1M
MDCO
31
DELISTED
Medicines Co
MDCO
$13.3M 0.23%
350,000
+250,000
+250% +$11.1M
ALXN
32
DELISTED
Alexion Pharmaceuticals
ALXN
$12.2M 0.21%
100,000
– –
IRWD icon
33
Ironwood Pharmaceuticals
IRWD
$602M
$11.6M 0.2%
736,554
-119,400
-14% -$1.73M
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
$11.5M 0.2%
140,000
+20,000
+17% +$1.5M
KITE
35
DELISTED
Kite Pharma, Inc.
KITE
$10.4M 0.18%
100,000
-30,000
-23% -$2.45M
ATH
36
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
$9.92M 0.17%
200,000
-250,000
-56% -$12.8M
RXDX
37
DELISTED
Ignyta, Inc.
RXDX
$9.31M 0.16%
900,000
-37,000
-4% -$300K
RDUS
38
CALL
DELISTED
Radius Health, Inc.
RDUS
$9.05M 0.16%
+200,000
New +$7.64M
HZNP
39
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.02M 0.16%
760,000
-40,000
-5% -$498K
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$7.95M 0.14%
950,000
+200,000
+27% +$1.64M
AGEN
41
Agenus
AGEN
$284M
$7.82M 0.14%
101,900
-10,190
-9% -$717K
MDCO
42
CALL
DELISTED
Medicines Co
MDCO
$7.6M 0.13%
+200,000
New +$8.91M
SAGE
43
DELISTED
Sage Therapeutics
SAGE
$7.17M 0.13%
90,000
-85,000
-49% -$6.14M
ATRA icon
44
Atara Biotherapeutics
ATRA
$73.7M
$7M 0.12%
20,000
– –
TSRO
45
DELISTED
TESARO, Inc.
TSRO
$6.99M 0.12%
50,000
– –
ZTO icon
46
ZTO Express
ZTO
$18.3B
$6.98M 0.12%
500,000
-450,000
-47% -$6.21M
IONS icon
47
Ionis Pharmaceuticals
IONS
$8.99B
$6.87M 0.12%
135,000
-115,000
-46% -$5.36M
GBT
48
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.84M 0.12%
+250,000
New +$7.44M
ELF icon
49
e.l.f. Beauty
ELF
$4.93B
$6.8M 0.12%
250,000
– –
RDUS
50
DELISTED
Radius Health, Inc.
RDUS
$6.79M 0.12%
150,000
-100,000
-40% -$3.82M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2017 Portfolio in Review

As of Q2 2017, Artal Group held 119 positions worth $5.72B, up 27% from $4.51B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group deployed $567M of net new capital in Q2 2017, opening 24 new positions and adding to 23 existing holdings. Its largest new stake was Goldman Sachs: 100,000 shares worth $22.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 35% of assets, down from 45% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Athene Holding Ltd. Class A Common Shares, an estimated $12.8M trimmed.

  • Artal Group's largest Q2 2017 buy was Goldman Sachs: 100,000 shares worth $22.2M.
  • Artal Group added most to Medicines Co in Q2 2017, an estimated $11.1M increase.
  • Artal Group's biggest Q2 2017 reduction was Athene Holding Ltd. Class A Common Shares, cutting an estimated $12.8M.
  • Artal Group fully exited Alibaba in Q2 2017, selling an estimated $27M.
  • Artal Group's ten largest holdings make up 85% of its $5.72B portfolio in Q2 2017.
  • Artal Group opened 24 new positions and closed 11 in Q2 2017.
  • Artal Group's portfolio value rose 27% quarter-over-quarter to $5.72B.

Based on Artal Group's 13F filing for Q2 2017, filed 11 Aug 2017.